Many patients with gouty arthritis experience frequent flares and have comorbidities that
may limit their anti-inflammatory treatment options for acute flare management. For patients
with contraindications to both NSAIDs and/or colchicine, treatment options are particularly
limited, and there is an unmet medical need in this subgroup of patients. Two phase 3
studies and their extensions have demonstrated that a single dose of canakinumab during
an acute flare provided rapid and effective pain relief and prolonged suppression of flares …